Valuation: SENSORION

Market Cap 129M 147M 119M 110M 209M 13.96B 212M 1.42B 553M 6.89B 552M 540M 23.81B P/E 2026 *
-16.7x
P/E 2027 * -3.85x
Enterprise Value -3.32M -3.79M -3.06M -2.84M -5.38M -360M -5.47M -36.69M -14.27M -178M -14.24M -13.94M -614M EV / Sales 2026 *
-0.15x
EV / Sales 2027 * 20.1x
Free-Float
70.51%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 59 2026-05-31
Director of Finance/CFO - 2024-06-25
Chief Tech/Sci/R&D Officer - 2023-12-10
Director TitleAgeSince
Director/Board Member - 2015-03-08
Director/Board Member 43 -
Chairman 61 2023-03-29
Change 5-day change 1-year change 3-year change Capi.($)
-1.03%+5.24%+2.94%+9.41% 50.25B
+0.25%+1.70%+419.39%+621.71% 40.39B
-0.16%+8.42%+28.20%+63.00% 34.4B
+1.10%+7.77%+28.18%-3.96% 34.38B
+1.31%-0.56%+5.12%+33.90% 26.32B
-0.35%+0.09% - - 16.64B
-3.33%+3.15%+71.30%+131.94% 16.14B
+3.79%+8.88%+106.63%+106.63% 13.75B
+0.32%+0.53%+14.33%+21.47% 13.71B
Average +0.21%+4.73%+84.51%+123.01% 27.33B
Weighted average by Cap. +0.09%+5.08%+95.81%+141.26%

Financials

2026 *2027 *
Net sales 21.86M 24.98M 20.14M 18.67M 35.44M 2.37B 36.02M 242M 93.93M 1.17B 93.77M 91.74M 4.04B 6.4M 7.31M 5.89M 5.46M 10.37M 694M 10.54M 70.67M 27.48M 342M 27.44M 26.84M 1.18B
Net income -4.34M -4.96M -4M -3.71M -7.04M -471M -7.15M -47.96M -18.65M -232M -18.62M -18.22M -803M -50.64M -57.87M -46.67M -43.26M -82.12M -5.49B -83.44M -560M -218M -2.71B -217M -213M -9.37B
Net Debt -132M -151M -122M -113M -214M -14.32B -217M -1.46B -567M -7.07B -566M -554M -24.42B -
Logo SENSORION
Sensorion is a clinical-stage biotech company, that specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. Sensorion has built a R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a proof of concept (PoC) clinical study in cisplatin-induced ototoxicity (CIO) and, with partner Cochlear Ltd, in a study in patients scheduled for cochlear implantation. Sensorion has entered into a strategic collaboration with Institut Pasteur. The company has two gene therapy programmes: SENS-501 for the treatment of hearing loss caused by otoferlin deficiency, and SENS-601 (GJB2-GT) for the treatment of hearing loss associated with mutations in the GJB2 gene.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-